Enterprise Value
5.359B
Cash
1.267B
Avg Qtr Burn
N/A
Short % of Float
2.98%
Insider Ownership
1.97%
Institutional Own.
89.03%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
COTELLIC (cobimetinib) Details Metastatic melanoma | Approved Quarterly sales | |
CABOMETYX (cabozantinib) Details Solid tumor/s, Renal cell carcinoma, Cancer | Approved Quarterly sales | |
COMETRIQ (cabozantinib) Details Metastatic MTC (Medullary Thyroid Cancer) | Approved Quarterly sales | |
Zanzalintinib Details Solid tumor/s, Cancer, Kidney cancer | Phase 3 Data readout | |
CABOMETYX (cabozantinib) + Nivolumab + Ipilimumab Details Solid tumor/s, Cancer, Kidney cancer | Phase 3 Data readout | |
CABOMETYX (cabozantinib) Details Cancer, Pancreatic cancer | Phase 3 Update | |
CABOMETYX (cabozantinib) + atezolizumab Details Solid tumor/s, Cancer, Castration-resistant prostate cancer | Phase 3 Update | |
Zanzalintinib + Pembrolizumab Details Cancer, Head and neck squamous cell carcinoma | Phase 2/3 Data readout | |
Zanzalintinib + AB521 Details Cancer, Kidney cancer | Phase 1/2 Initiation | |
Zanzalintinib Details Solid tumor/s, Cancer | Phase 1b Data readout | |
Zanzalintinib +/- atezolizumab Details Solid tumor/s, Cancer, Carcinoma | Phase 1b Update | |
CBX-12 (topoisomerase I inhibition) Details Solid tumor/s, Cancer | Phase 1 Update |